Showing 4221-4230 of 6411 results for "".
- Study: This Is When to Use Adjuvant Therapy in Patients with Early Stage 3A Melanomahttps://practicaldermatology.com/news/study-this-is-when-to-use-adjuvant-therapy-in-patients-with-early-stage-3a-melanoma/2461313/
- CeraVe, Top Derms, and Skincare Enthusiasts Partner to Teach Consumers to #CleanseLikeaDermhttps://practicaldermatology.com/news/cerave-top-derms-and-skincare-enthusiasts-partner-to-teach-consumers-to-cleanselikeaderm/2461283/CeraVe is teaming up with board-certified dermatologists and two of the biggest dermatologist influencers on social media today – Dr. Dustin Portela (@208skindoc) and Dr. Michelle Henry (@drmichellehenry) – to host a global livestreamed event with skincare enthusiast and content creat
- Happify Health, Almirall Go Live with Digital Solution to Support Psoriasis Patientshttps://practicaldermatology.com/news/happify-health-almirall-go-live-with-digital-solution-to-support-psoriasis-patients/2461234/Happify Health and Almirall S.A.’s new digital platform Claro is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was built to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and m
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- Handheld Device May Painlessly Identify Skin Cancershttps://practicaldermatology.com/news/handheld-device-may-painlessly-identify-skin-cancers/2461188/Researchers at Stevens Institute of Technology are developing a low-cost handheld device that could cut the rate of unnecessary biopsies in half and give dermatologists and other frontline physicians easy access to laboratory-grade cancer diagnostics. “We aren’t trying
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Der
- Lilly's Olumiant Associated with Significant Hair Growth in Patients with Severe Alopecia Areatahttps://practicaldermatology.com/news/lillys-olumiant-associated-with-significant-hair-growth-in-patients-with-severe-alopecia-areata/2461144/Olumiant® (baricitinib) from Eli Lilly and company produced significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks, with nearly 75% of those who responded to Olumiant 4mg achieving 90% scalp coverage. The 52-week pooled findings were presented at the
- Data Demonstrate Safety, Efficacy of Dupilumab for AD in Patients as Young as Six Monthshttps://practicaldermatology.com/news/data-demonstrate-safety-efficacy-of-dupilumab-for-ad-in-patients-as-young-as-six-months/2461005/Data demonstrating the safety and efficacy of Sanofi and Regeneron’s
- Study: Infection Rates in PsA Patients on Biologics Are Decreasinghttps://practicaldermatology.com/news/study-infection-rates-in-psa-patients-on-biologics-are-decreasing/2460979/Infection rates among people with psoriatic arthritis (PsA) taking biologics decreased from 2012 to 2017, according to new research presented at ACR Convergence, the American College of Rheumatology’s an